Condition: Autoimmune Lymphoproliferative Syndrome · Autoimmune Cytopenia · Autoimmune Diseases · Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).
This description comes directly from the study's public registry record.
Frédéric Rieux-Laucat · +33142754200 · frederic.rieux-laucat@inserm.fr
Always discuss trial participation with your own doctor first.
| hôpital Necker Enfants Malades | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04902807